December 05, 2018
Sponsored by
Agena Bioscience

Validating a Diagnostic Mass Spec Platform for a Molecular Pathology Service Lab


Join or Log in for Access

This content is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This webinar will describe how a molecular pathology laboratory selected and validated a mass spectrometry-based analysis platform for diagnostic use.

Doug Demetrick, director of the Molecular Pathology Laboratory at Calgary Laboratory Services, will share his experience implementing the Agena MassArray platform in his lab.

This presentation will focus on the Agena iPLEX HS chemistry, which enables solid tumor profiling in lung, colon, melanoma, and brain samples. Dr. Demetrick will also discuss his ongoing work to enable liquid biopsy using the Agena UltraSeek chemistry.

Sponsored by

The New York Times and ProPublica say that many physicians fail to disclose their financial ties when publishing in medical journals.

The Wall Street Journal reports Human Longevity's valuation has dropped by 80 percent.

Science reports that the US National Cancer Institute is cutting its operating budget by 5 percent.

In PLOS this week: similar variants seen in bullbogs, people with Robinow syndrome; ApoE genotypes in African-American, Puerto Rican populations; and more.